Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Marvell Technology Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Marvell Technology Inc trades at $224.92 (market cap $190.94B). The key difference: Marvell Technology Inc is far larger — about 23.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Marvell Technology Inc pays a 0.11% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | MRVL | |
|---|---|---|
Market Cap | $8.02B | $190.94B |
Sector | Health | Technology |
52-Week High | $339.75 | $316.43 |
52-Week Low | $241.71 | $62.31 |
Enterprise Value | $7.84B | $192.37B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Marvell Technology (MRVL) trades at $217.53, down 7.75% over the past day, reflecting recent market volatility. The stock shows strong analyst support with an 82% buy rating and a consensus price target of $275.68, indicating significant upside potential. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.80 surpassing the $0.798 estimate. However, the company reported a net loss of $885 million for 2025, though revenue grew to $5.77 billion. Technical indicators are bearish, with the price near key support at $213.
The outlook for MRVL is positive due to its positioning in custom AI chips and optical networking, with projected revenue growth to $8.7 billion in 2026. Risks include high valuation multiples (P/E of 74.75) and competitive pressures from peers like Nvidia and Broadcom. Investors should weigh the strong analyst optimism against fundamental challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
